Search Results for "Immunizations"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Immunizations. Results 291 to 300 of 421 total matches.
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
common bacterial pathogens. Since the introduction
of routine pneumococcal vaccination ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Rocuronium - A New Neuromuscular Blocker
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994 (Issue 928)
bromide Zemuron Vecuronium Correction typhoid vaccine correction Tracrium Succinylcholine ...
Rocuronium bromide (Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Alpha-L-Iduronidase (Laronidase; Aldurazyme)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
developed antibodies to the enzyme early in treatment developed immune tolerance (no antibody response) over ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Capsaicin Patch (Qutenza) for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • May 30, 2011 (Issue 1365)
of the
patch. o
1. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006;
48: 73.
The Medical Letter ...
The FDA has approved a topical 8% patch formulation
of capsaicin (Qutenza – NeurogesX), available only by
prescription, for local treatment of postherpetic neuralgia.
Postherpetic neuralgia occurs after herpes zoster
in about one third of patients ≥60 years old and can
persist for months or even years.
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011 (Issue 1366)
— In the higher doses used to
suppress cardiac arrhythmias, quinidine can cause
immune-mediated thrombocytopenia ...
The FDA has approved Nuedexta (Avanir), a fixed-dose
combination of the cough suppressant dextromethorphan
hydrobromide and the antiarrhythmic
quinidine sulfate, for oral treatment of pseudobulbar
affect. The combination is the first treatment approved
by the FDA for this indication. Studies to support the
effectiveness of Nuedexta were performed in patients
with underlying amyotrophic lateral sclerosis (ALS) or
multiple sclerosis (MS); the drug has not been shown to
be safe or effective in other types of emotional lability.
Tocilizumab (Actemra) for Giant Cell Arteritis
The Medical Letter on Drugs and Therapeutics • Sep 25, 2017 (Issue 1530)
tuberculosis is required
before starting the drug. Live vaccines should not be
administered during ...
The FDA has approved the interleukin-6 (IL-6) receptor
antagonist tocilizumab (Actemra – Genentech) for
subcutaneous (SC) treatment of giant cell arteritis
in adults. It is the first drug to be approved in the US
for this indication. Tocilizumab is also approved for
treatment of rheumatoid arthritis, polyarticular or
systemic juvenile idiopathic arthritis, and cytokine
release syndrome.
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
may interfere
with immune responses to infection. Hypersensitivity
reactions have occurred rarely.
Letter ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
the risks of cytokine release
syndrome (CRS) and life-threatening or fatal immune
effector cell-associated ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Talquetamab (Talvey) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
warning about the risks of cytokine release
syndrome (CRS) and neurologic toxicity, including
immune ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific
GPRC5D-directed T-cell engager, has been granted
accelerated approval by the FDA for treatment of
relapsed or refractory multiple myeloma in adults
who received ≥4 prior lines of therapy, including a
proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Accelerated
approval was based on the response rate and
durability of response. Talquetamab is the first
bispecific GPRC5D-directed T-cell engager to be
approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50 doi:10.58347/tml.2023.1684e | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
of efavirenz and valoctocogene
roxaparvovec is not recommended. Live vaccines
should not be administered ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction